List Prices of Enbrel, Stelara Slashed by Close to 70% Through Medicare Price Negotiations
The list prices of Stelara (ustekinumab) and Enbrel (etanercept) for people on Medicare will be reduced by nearly 70% in 2026, the White House announced. This action is a result of the first round of Centers for Medicare & Medicaid Services (CMS) price negotiations with drugmakers. It comprises the 10 costliest prescription drugs under Medicare. […]